KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $13.2 million.

  • Acadia Pharmaceuticals' Share-based Compensation fell 4962.54% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.3 million, marking a year-over-year decrease of 3386.67%. This contributed to the annual value of $67.0 million for FY2024, which is 94.55% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Share-based Compensation stood at $13.2 million, which was down 4962.54% from $14.3 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Share-based Compensation's 5-year high stood at $26.2 million during Q3 2024, with a 5-year trough of $10.4 million in Q4 2024.
  • Its 5-year average for Share-based Compensation is $16.0 million, with a median of $15.0 million in 2022.
  • In the last 5 years, Acadia Pharmaceuticals' Share-based Compensation surged by 4112.95% in 2024 and then tumbled by 4962.54% in 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Share-based Compensation (Quarter) stood at $12.9 million in 2021, then rose by 11.91% to $14.4 million in 2022, then rose by 25.04% to $18.0 million in 2023, then plummeted by 42.02% to $10.4 million in 2024, then rose by 26.12% to $13.2 million in 2025.
  • Its Share-based Compensation stands at $13.2 million for Q3 2025, versus $14.3 million for Q2 2025 and $11.4 million for Q1 2025.